Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Viatris Inc. (VTRS : NSDQ)
 
 • Company Description   
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.

Number of Employees: 32,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.32 Daily Weekly Monthly
20 Day Moving Average: 11,037,964 shares
Shares Outstanding: 1,173.68 (millions)
Market Capitalization: $10,938.72 (millions)
Beta: 0.89
52 Week High: $13.55
52 Week Low: $6.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 10.16% 4.20%
12 Week 28.38% 7.70%
Year To Date -25.14% -29.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1000 MYLAN BOULEVARD
-
CANONSBURG,PA 15317
USA
ph: 724-514-1800
fax: 724-514-1870
investorrelations@viatris.com http://www.viatris.com
 
 • General Corporate Information   
Officers
Scott A. Smith - Chief Executive Officer
Melina Higgins - Chairperson
Mark Parrish - Vice Chairman
Theodora Mistras - Chief Financial Officer
W. Don Cornwell - Director

Peer Information
Viatris Inc. (CHCR)
Viatris Inc. (ESRX)
Viatris Inc. (MYDP)
Viatris Inc. (COR)
Viatris Inc. (GBCS)
Viatris Inc. (LAXAF)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Medical Services
Sector: Medical
CUSIP: 92556V106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 1,173.68
Most Recent Split Date: 10.00 (1.50:1)
Beta: 0.89
Market Capitalization: $10,938.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 5.15%
Current Fiscal Quarter EPS Consensus Estimate: $0.63 Indicated Annual Dividend: $0.48
Current Fiscal Year EPS Consensus Estimate: $2.25 Payout Ratio: 0.19
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: 0.07
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: 05/23/2025 - $0.12
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 4.15
Trailing 12 Months: 3.76
PEG Ratio: -
Price Ratios
Price/Book: 0.71
Price/Cash Flow: 1.83
Price / Sales: 0.76
EPS Growth
vs. Year Ago Period: -25.37%
vs. Previous Quarter: -7.41%
Sales Growth
vs. Year Ago Period: -11.17%
vs. Previous Quarter: -7.76%
ROE
06/30/25 - -
03/31/25 - 16.20
12/31/24 - 16.38
ROA
06/30/25 - -
03/31/25 - 7.01
12/31/24 - 7.14
Current Ratio
06/30/25 - -
03/31/25 - 1.68
12/31/24 - 1.65
Quick Ratio
06/30/25 - -
03/31/25 - 0.97
12/31/24 - 0.98
Operating Margin
06/30/25 - -
03/31/25 - 20.80
12/31/24 - 21.66
Net Margin
06/30/25 - -
03/31/25 - -26.45
12/31/24 - -4.30
Pre-Tax Margin
06/30/25 - -
03/31/25 - -27.39
12/31/24 - -4.23
Book Value
06/30/25 - -
03/31/25 - 13.20
12/31/24 - 15.61
Inventory Turnover
06/30/25 - -
03/31/25 - 2.27
12/31/24 - 2.32
Debt-to-Equity
06/30/25 - -
03/31/25 - 1.02
12/31/24 - 0.75
Debt-to-Capital
06/30/25 - -
03/31/25 - 50.59
12/31/24 - 42.97
 

Powered by Zacks Investment Research ©